On March 8, 2022 Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, reported several poster presentations at upcoming scientific conferences that support the ongoing investigation of its clinical and preclinical pipeline (Press release, Arcus Biosciences, MAR 8, 2022, View Source [SID1234609708]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"Scientific exchange fosters progress in research, and we value the opportunity to contribute to the advancement of cancer research by presenting early data that support the clinical approach to investigating our molecules," said Terry Rosen, Ph.D., Chief Executive Officer of Arcus. "The AB521 data presented at the ESMO (Free ESMO Whitepaper) TAT Congress confirm its potential to have an improved clinical profile compared to that of the approved HIF-2a inhibitor; we plan to advance this molecule into a Phase 1/1b study in patients with clear-cell renal cell carcinoma in mid-2022. Etrumadenant, quemliclustat and zimberelimab are already being investigated in randomized and late-stage studies across common cancers like colon, lung, pancreas and prostate."

ESMO Targeted Anticancer Therapies Congress, March 7-8, 2022

Title: AB521, a Clinical-Stage, Potent, and Selective Hypoxia-Inducible Factor (HIF)-2α Inhibitor, for the Treatment of Renal Cell Carcinoma
Abstract number: 252

American Society for Clinical Pharmacology & Therapeutics (ASCPT), March 16-18, 2022

Title: A Mechanistic Pharmacokinetic-Pharmacodynamic (PK-PD) Model of Quemliclustat (AB680), a Small-Molecule Inhibitor of CD73, in Healthy Volunteers and Patients with Gastrointestinal Malignancies
Abstract number: P-102

Title: Population Pharmacokinetics and Pharmacodynamics of Etrumadenant (AB928) in Healthy Volunteers and Cancer Patients
Abstract number: P-196

Title: Population Pharmacokinetics of Zimberelimab (AB122) and Dose Justification by Model Informed Drug Development (MIDD) Approach
Abstract number: P-032

American Association for Cancer Research, April 8-13, 2022

Title: Inhibition of CD39 Results in Elevated ATP and Activation of Myeloid Cells to Promote Anti-Tumor Immunity
Abstract number: 4151

Title: Dual A2aR/A2bR Antagonism with Etrumadenant (AB928) Eliminates the Suppressive Effects of Adenosine on Immune and Cancer Cells in the Tumor Microenvironment
Abstract number: 2728

Title: HPK1 Inhibition Enhances T Cell Activation and Relieves the Immunosuppressive Phenotype of Inhibitory Signals Found in the Tumor Microenvironment
Abstract number: 5762

Arcus Clinical Study Overview

Trial
Name

Arms

Setting

Status

NCT No.

Lung Cancer

ARC-7

zim vs. zim + dom vs. zim +
dom + etruma

1L NSCLC (PD-L1 ≥ 50%)

Ongoing
Randomized
Phase 2

NCT04262856

PACIFIC-8

durva ± dom

Curative-Intent Stage 3 NSCLC

Ongoing
Registrational
Phase 3

NCT05211895

ARC-10

chemo vs. zim vs. zim + dom

1L NSCLC (PD-L1 ≥ 50%)

Ongoing
Registrational
Phase 3

NCT04736173

Colon Cancer

ARC-9

etruma + zim + mFOLFOX vs.
SOC

2L/3L/3L+ CRC

Ongoing
Randomized
Phase 2

NCT04660812

Pancreatic Cancer

ARC-8

quemli + zim + gem/nab-pac
vs. quemli + gem/nab-pac

1L, 2L PDAC

Ongoing
Randomized
Phase 1/1b

NCT04104672

Prostate Cancer

ARC-6

etruma + zim + SOC vs. SOC

2L/3L CRPC

Ongoing
Randomized
Phase 2

NCT04381832

Various

ARC-12

AB308 + zim

Advanced Malignancies

Ongoing
Phase 1/1b

NCT04772989

ARC-14

AB521

Healthy Volunteer

Ongoing
Phase 1

NCT05117554

Carbo/pem: carboplatin/pemetrexed; dom: domvanalimab; durva: durvalumab; etruma: etrumadenant; gem/nab-pac: gemcitabine/nab-paclitaxel; quemli: quemliclustat; R/R: relapsed/refractory; SOC: standard of care; zim: zimberelimab CRC: colorectal cancer; CRPC: castrate-resistant prostate cancer; NSCLC: non-small cell lung cancer; PDAC: pancreatic ductal adenocarcinoma